The impact of direct oral anticoagulants on hip fracture care in Australia and New Zealand: a prospective patient sprint audit
- PMID: 40828478
- DOI: 10.1007/s00198-025-07659-y
The impact of direct oral anticoagulants on hip fracture care in Australia and New Zealand: a prospective patient sprint audit
Abstract
Management of hip fracture patients on direct oral anticoagulants in Australia and New Zealand is unclear. Hip fracture patients on DOACs had three times higher odds of time to surgery > 36 h than patients on no antithrombotic medication. Balancing individual considerations and guidelines may shorten time to surgery.
Purpose: The management of hip fracture patients taking direct oral anticoagulants (DOACs) requires balancing anticoagulation concerns and adherence to recommendations of surgery within 36 h. This study compares the management and time to surgery of hip fracture patients in Australia and New Zealand who were on DOACs, other antithrombotic medication, and no antithrombotic medication.
Method: A sprint audit of hospitals participating in the Australian and New Zealand Hip Fracture Registry (ANZHFR) was conducted. Sprint audit data regarding DOAC use, demographics, and clinical management was collected for consecutive patients aged ≥ 50 years admitted to hospital with a hip fracture between 1 June and 30 July 2024. The primary outcome was time to surgery.
Results: Of 1043 hip fracture patients, 192 (18%) were taking DOACs on presentation to hospital. Patients on DOACs had 3 times higher odds (OR 3.65, 95% CI 2.40-5.55), and patients on other antithrombotic medication had 1.6 times higher odds (OR 1.62, 95% CI 1.12-2.34) of time to surgery > 36 h, compared to patients on no antithrombotic medication. The median time to surgery for patients on DOACs was 39 h (IQR 24-48); for patients on no or other antithrombotic medication, time to surgery was 25 h (IQR 20-39) and 27 h (IQR 20-44), respectively. There were no differences in the proportion of patients who had perioperative blood transfusions.
Conclusions: Patients on DOACs are likely to experience delays to surgery compared to patients on no antithrombotic medication, beyond what patients on other antithrombotic medications may experience.
Keywords: Audit; Direct oral anticoagulant; Hip fracture; Registry.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics: The DOAC sprint audit and the ANZHFR have ethical approval from a lead Human Research Ethics Committee in each Australian jurisdiction and in New Zealand and local governance approvals from each participating hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the jurisdictional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Conflicts of interest: None.
Similar articles
-
A comparison of the effects of direct oral anticoagulants versus vitamin K antagonists and antiplatelet agents on the timing and outcomes of hip fracture surgery in patients older than 65 years: the ORTHO-GER-DOAC study.Eur Geriatr Med. 2025 Jun;16(3):899-907. doi: 10.1007/s41999-025-01198-9. Epub 2025 Apr 23. Eur Geriatr Med. 2025. PMID: 40266484 Free PMC article.
-
Synthesis of the evidence on the impact of pre-operative direct oral anticoagulants on patient health outcomes after hip fracture surgery: rapid systematic review.Eur J Trauma Emerg Surg. 2022 Aug;48(4):2567-2587. doi: 10.1007/s00068-022-01937-8. Epub 2022 Mar 11. Eur J Trauma Emerg Surg. 2022. PMID: 35275244 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.Cochrane Database Syst Rev. 2016 Mar 30;3(3):CD004179. doi: 10.1002/14651858.CD004179.pub2. Cochrane Database Syst Rev. 2016. PMID: 27027384 Free PMC article.
-
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD011762. doi: 10.1002/14651858.CD011762.pub2. Cochrane Database Syst Rev. 2025. PMID: 39868562
References
-
- Dong Y, Zhang Y, Song K et al (2023) What was the epidemiology and global burden of disease of hip fractures from 1990 to 2019? Results from and additional analysis of the Global Burden of Disease Study 2019. Clin Orthop Relat Res. https://doi.org/10.1097/corr.0000000000002465 - DOI - PubMed - PMC
-
- Australian and New Zealand Hip Fracture Registry Steering Group (2014) Australian and New Zealand guideline for hip fracture care: improving outcomes in hip fracture management of adults. Australian and New Zealand Hip Fracture Registry Steering Group, Sydney
-
- Australian Commission on Safety and Quality in Health Care (2023) Hip Fracture Clinical Care Standard. ACSQHC, Sydney
-
- National Institute for Health Care Excellence (2011) The management of hip fracture in adults. NICE, Manchester. https://www.nice.org.uk/guidance/cg124
-
- Harvey L, Taylor ME, Harris IA et al (2024) Adherence to clinical care standards and mortality after hip fracture surgery in New South Wales, 2015–2018: a retrospective population-based study. Med J Aust. https://doi.org/10.5694/mja2.52470 - DOI - PubMed
LinkOut - more resources
Full Text Sources